HilleVax, Inc. (HLVX)

US — Healthcare Sector
Peers: PMVP  ELYM  MNOV  PHVS  PEPG  MOLN  GLUE  TRDA  VIGL  IPSC  EWTX  CCCC  MLYS  CGEM  PRDS  STTK  CSBR  NAMSW  CNTA  STRO  OPT 

Automate Your Wheel Strategy on HLVX

With Tiblio's Option Bot, you can configure your own wheel strategy including HLVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol HLVX
  • Rev/Share 0.0
  • Book/Share 3.0194
  • PB 0.6392
  • Debt/Equity 0.1593
  • CurrentRatio 25.3184
  • ROIC -0.5962

 

  • MktCap 96772254.0
  • FreeCF/Share -1.8082
  • PFCF -1.0708
  • PE -0.9058
  • Debt/Assets 0.1344
  • DivYield 0
  • ROE -0.6133

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About HilleVax, Inc. (HLVX)

  • IPO Date 2022-04-29
  • Website https://www.hillevax.com
  • Industry Biotechnology
  • CEO Dr. Robert M. Hershberg M.D., Ph.D.
  • Employees 14
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.